Business Context and Reporting Period
This Form 8-K is a current report filed by Cerulean Pharma Inc. on March 19, 2015. The filing announces operational highlights for the fourth quarter and the full year ended December 31, 2014, along with anticipated corporate and clinical milestones for 2015 and 2016. The detailed financial and operational data is contained in a press release furnished as Exhibit 99.1.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being included in the press release (Exhibit 99.1) but are not explicitly stated within the body of this Form 8-K.
Material Changes
The filing does not detail specific material changes versus prior periods in the text provided. It serves as a notification that the Company has issued a press release containing these operational highlights and financial results.
Guidance, Outlook, and Risks
- Outlook: The Company provided anticipated corporate and clinical milestones for the remainder of 2015 and 2016.
- Legal Status: The information in Item 2.02 and Exhibit 99.1 is deemed "furnished" rather than "filed" under Section 18 of the Exchange Act and is not subject to the liabilities of that section.
- Risks: No specific risk factors or contingencies are detailed in the text of this Form 8-K.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated March 19, 2015) for specific Q4 and full-year 2014 financial figures.
- Verify the specific clinical milestones anticipated for 2015 and 2016 as outlined in the press release.
- Confirm the Company's current cash position and burn rate, as these are not listed in the 8-K summary text.
- Note that the financial data in the press release is not incorporated by reference into this filing for liability purposes under Section 18.